These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26342235)

  • 21. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
    Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
    Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 23. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-Driven Treatments Yield Better Results.
    Cancer Discov; 2016 Aug; 6(8):OF4. PubMed ID: 27357459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular classification and drug response prediction in cancer.
    Creighton CJ
    Curr Drug Targets; 2012 Nov; 13(12):1488-94. PubMed ID: 22974392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug sensitivity testing platforms for gastric cancer diagnostics.
    Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
    J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steps forward for cancer precision medicine.
    Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D;
    Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The RACE to Develop New Targeted Therapies for Children With CNS Tumors.
    Fletcher EP; Burckart GJ; Robinson GW; Reaman GH; Stewart CF
    Clin Pharmacol Ther; 2020 Sep; 108(3):434-436. PubMed ID: 32638364
    [No Abstract]   [Full Text] [Related]  

  • 29. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
    Bao J; Qiao L
    Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
    [No Abstract]   [Full Text] [Related]  

  • 30. The promise of ESCAT: a new system for evaluating cancer drug-target pairs.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2019 Mar; 16(3):147-148. PubMed ID: 30317250
    [No Abstract]   [Full Text] [Related]  

  • 31. Genomic Profiling of Cancers of Unknown Primary Site--Reply.
    Ross JS; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Jul; 1(4):542-3. PubMed ID: 26181269
    [No Abstract]   [Full Text] [Related]  

  • 32. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
    Cobain EF; Chinnaiyan AM; Kurzrock R; Baker LH
    JAMA Oncol; 2015 Jul; 1(4):542. PubMed ID: 26181268
    [No Abstract]   [Full Text] [Related]  

  • 33. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
    Varghese AM; Saltz LB
    JAMA Oncol; 2015 Jul; 1(4):541-2. PubMed ID: 26181267
    [No Abstract]   [Full Text] [Related]  

  • 34. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
    Whang YE; Hayes DN
    JAMA Oncol; 2015 Jul; 1(4):541. PubMed ID: 26181266
    [No Abstract]   [Full Text] [Related]  

  • 35. Pairing Cancer Biomarkers to Biomedicine.
    Shin SH; Dong Z
    EBioMedicine; 2017 Nov; 25():1-2. PubMed ID: 29113773
    [No Abstract]   [Full Text] [Related]  

  • 36. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine?
    Varadhachary G
    JAMA Oncol; 2015 Apr; 1(1):19-21. PubMed ID: 26182299
    [No Abstract]   [Full Text] [Related]  

  • 38. Companion diagnostic testing for targeted cancer therapies: an overview.
    Fan YS
    Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
    Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
    Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical medicine. Biomarker tests need closer scrutiny, IOM concludes.
    Kaiser J
    Science; 2012 Mar; 335(6076):1554. PubMed ID: 22461579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.